loading page

Mpox in the New York Metropolitan area, Summer 2022
  • +5
  • Marina Keller,
  • Rachel Gnanaprakasam,
  • Rebecca Glassman,
  • Marc El-Khoury,
  • Donald Chen S,
  • Nicholas Feola,
  • Jared Feldman,
  • Vishnu Chaturvedi
Marina Keller
Westchester Medical Center

Corresponding Author:marina.keller@wmchealth.org

Author Profile
Rachel Gnanaprakasam
Westchester Medical Center
Author Profile
Rebecca Glassman
Westchester Medical Center
Author Profile
Marc El-Khoury
Westchester Medical Center
Author Profile
Donald Chen S
Westchester Medical Center
Author Profile
Nicholas Feola
Westchester Medical Center
Author Profile
Jared Feldman
Westchester Medical Center
Author Profile
Vishnu Chaturvedi
Westchester Medical Center
Author Profile

Abstract

Early in the 2022 Mpox (MPX) global outbreak, caseloads in the New York Metropolitan area climbed rapidly before other US urban areas. This case series summarizes the authors’ clinical experience detecting and treating MPX, during a quickly evolving outbreak. Clinical outcomes were recorded with a focus on varied clinical presentation and outcomes such as complications and response to experimental tecovirimat therapy. A focal or multifocal rash was the most common presenting symptom in 91% of patients. Almost two thirds (62%) of patients had anogenital involvement. Proctitis was one of the most painful presentations with 75% requiring antiviral treatment and 3 patients needing hospitalization for pain management. Most patients responded promptly to antiviral treatment with tecovirimat. Five out of 10 patients treated with tecovirimat reported symptom resolution within 48 – 72 hours of therapy and another 3 saw resolution within first 96 hours. Two patients had poor response to tecovirimat. This series includes the only reported case of an HIV positive, immunocompetent patient who experienced recurrent anal ulcers due to Mpox and required a second course of tecovirimat. Other unique presentations included urethritis, abscess formation and MPX infection post-vaccination. Control of this current Mpox outbreak was possible due to timely diagnosis and the availability of both a licensed vaccine and an investigational drug.
14 Feb 2023Submitted to Journal of Medical Virology
14 Feb 2023Submission Checks Completed
14 Feb 2023Assigned to Editor
14 Feb 2023Review(s) Completed, Editorial Evaluation Pending
19 Feb 2023Reviewer(s) Assigned
06 Mar 2023Editorial Decision: Revise Minor
16 Mar 20231st Revision Received
17 Mar 2023Submission Checks Completed
17 Mar 2023Assigned to Editor
17 Mar 2023Review(s) Completed, Editorial Evaluation Pending
17 Mar 2023Editorial Decision: Accept